Cargando…
Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy
PURPOSE: The study aimed to establish a prognostic prediction model and an artificial neural network (ANN) model to determine who will benefit from transarterial chemoembolization (TACE) monotherapy for patients with hepatocellular carcinoma (HCC) invading portal vein. METHODS: Treatment-naïve patie...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
KeAi Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562278/ https://www.ncbi.nlm.nih.gov/pubmed/34805935 http://dx.doi.org/10.1016/j.jimed.2020.08.001 |
_version_ | 1784593230913863680 |
---|---|
author | Zhang, Lei Zhong, BinYan Hu, Bo Li, Wei Huang, Peng Zhang, Shen Song, JinJin Ji, JianSong Ni, CaiFang |
author_facet | Zhang, Lei Zhong, BinYan Hu, Bo Li, Wei Huang, Peng Zhang, Shen Song, JinJin Ji, JianSong Ni, CaiFang |
author_sort | Zhang, Lei |
collection | PubMed |
description | PURPOSE: The study aimed to establish a prognostic prediction model and an artificial neural network (ANN) model to determine who will benefit from transarterial chemoembolization (TACE) monotherapy for patients with hepatocellular carcinoma (HCC) invading portal vein. METHODS: Treatment-naïve patients with HCC and portal vein invasion who were treated with TACE monotherapy at hospital A as training cohort and hospital B as validation cohort were included. The primary endpoint was overall survival (OS). In training cohort, independent risk factors associated with OS were identified by univariate and multivariate analysis. The prognostic prediction (PP) and ANN models based on the independent risk factors were established to find out who will benefit most from TACE monotherapy. The type of portal vein tumor thrombosis was classified based on the Cheng’s Classification. The accuracy of the models was validated in validation cohort. RESULTS: Totally, 242 patients (training cohort: n = 159; validation cohort: n = 83) were included. The median OS was 7.1 and 8.5 months in training and validation cohort, respectively. In training cohort, the PP model was established based on the following five independent risk factors: Cheng’s Classification, Eastern Cooperative Oncology Group score, maximum tumor size, number of HCC nodules, and Child-Pugh stage. PP score of 17.5 was identified as cut-off point and patients were divided into two groups by PP score <17.5 and >17.5 in survival benefit and prognostication (8.8 vs. 5.5 months; P < 0.001). These five factors were included and ranked based on the importance associated with OS in the ANN model. Both of the two models received high accuracy after validation. CONCLUSIONS: Portal vein invaded HCC patients with PP score <17.5 may benefit most from TACE monotherapy. For these patients, TACE monotherapy should be considered. |
format | Online Article Text |
id | pubmed-8562278 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | KeAi Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85622782021-11-19 Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy Zhang, Lei Zhong, BinYan Hu, Bo Li, Wei Huang, Peng Zhang, Shen Song, JinJin Ji, JianSong Ni, CaiFang J Interv Med Article PURPOSE: The study aimed to establish a prognostic prediction model and an artificial neural network (ANN) model to determine who will benefit from transarterial chemoembolization (TACE) monotherapy for patients with hepatocellular carcinoma (HCC) invading portal vein. METHODS: Treatment-naïve patients with HCC and portal vein invasion who were treated with TACE monotherapy at hospital A as training cohort and hospital B as validation cohort were included. The primary endpoint was overall survival (OS). In training cohort, independent risk factors associated with OS were identified by univariate and multivariate analysis. The prognostic prediction (PP) and ANN models based on the independent risk factors were established to find out who will benefit most from TACE monotherapy. The type of portal vein tumor thrombosis was classified based on the Cheng’s Classification. The accuracy of the models was validated in validation cohort. RESULTS: Totally, 242 patients (training cohort: n = 159; validation cohort: n = 83) were included. The median OS was 7.1 and 8.5 months in training and validation cohort, respectively. In training cohort, the PP model was established based on the following five independent risk factors: Cheng’s Classification, Eastern Cooperative Oncology Group score, maximum tumor size, number of HCC nodules, and Child-Pugh stage. PP score of 17.5 was identified as cut-off point and patients were divided into two groups by PP score <17.5 and >17.5 in survival benefit and prognostication (8.8 vs. 5.5 months; P < 0.001). These five factors were included and ranked based on the importance associated with OS in the ANN model. Both of the two models received high accuracy after validation. CONCLUSIONS: Portal vein invaded HCC patients with PP score <17.5 may benefit most from TACE monotherapy. For these patients, TACE monotherapy should be considered. KeAi Publishing 2020-08-16 /pmc/articles/PMC8562278/ /pubmed/34805935 http://dx.doi.org/10.1016/j.jimed.2020.08.001 Text en © 2020 Shanghai Journal of Interventional Medicine Press. Production and hosting by Elsevier B.V. on behalf of KeAi. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Zhang, Lei Zhong, BinYan Hu, Bo Li, Wei Huang, Peng Zhang, Shen Song, JinJin Ji, JianSong Ni, CaiFang Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy |
title | Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy |
title_full | Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy |
title_fullStr | Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy |
title_full_unstemmed | Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy |
title_short | Stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy |
title_sort | stratification of portal vein-invaded hepatocellular carcinoma treated with transarterial chemoembolization monotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562278/ https://www.ncbi.nlm.nih.gov/pubmed/34805935 http://dx.doi.org/10.1016/j.jimed.2020.08.001 |
work_keys_str_mv | AT zhanglei stratificationofportalveininvadedhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmonotherapy AT zhongbinyan stratificationofportalveininvadedhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmonotherapy AT hubo stratificationofportalveininvadedhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmonotherapy AT liwei stratificationofportalveininvadedhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmonotherapy AT huangpeng stratificationofportalveininvadedhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmonotherapy AT zhangshen stratificationofportalveininvadedhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmonotherapy AT songjinjin stratificationofportalveininvadedhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmonotherapy AT jijiansong stratificationofportalveininvadedhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmonotherapy AT nicaifang stratificationofportalveininvadedhepatocellularcarcinomatreatedwithtransarterialchemoembolizationmonotherapy |